Interestingly, combinatorial inhibition of IDO1, IDO2, and TDO2 (together thought to be the predominant rate-limiting enzymes for the kynurenine pathway) did not impact tumor viability in patient derived GBM cells [55]. The gene discussed is IDO1; the disease is glioblastoma.